admin
Brito-Zeron, P. et al. Sjögren syndrome. Nat. Rev. Dis. Prim. 2, 16047 (2016).
McCoy, S. S. et al. Symptom-based cluster analysis categorizes Sjögren’s disease subtypes: an international cohort study highlighting disease severity and treatment discordance. Arthritis Rheumatol. 74, 1569–1579 (2022).
Ramos-Casals, M., Brito-Zeron, P., Siso-Almirall, A. & Bosch, X. Primary Sjögren syndrome. Praxis 101, 1565–1571 (2012).
Gougerot, H. Insuffisance progressive et atrophie des glandes salivaires et muqueuses de la bouche, des conjonctives (et parfois des muqueuses nasale, laryngée, vulvaire), “sécheresse” de la bouche, des conjonctives, etc. Bull. Soc. Franc. Derm. Syph. 32, 376–379 (1925).
Sjögren, H. Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol. 11, 1–151 (1933).
Jonsson, R. Henrik Sjögren (1899-1986): the syndrome and his legacy. Ann. Rheum. Dis. 80, 1108–1109 (2021).
Von Grósz, S. Aetiologie und Therapie der Keratoconjunctivitis sicca. Klin. Med. Augenheilk 97, 472–485 (1936).
Sjögren H. A New Conception of Keratoconjunctivitis Sicca: Keratitis Filiformis in Hypofunction of the Lachrymal Glands (Australasian Medical Publishing Company Limited, 1943).
Bloch, K. J., Buchanan, W. W., Wohl, M. J. & Bunim, J. J. Sjögren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine 44, 187–231 (1965).
Moutsopoulos, H. M., Mann, D. L., Johnson, A. H. & Chused, T. M. Genetic differences between primary and secondary sicca syndrome. N. Engl. J. Med. 301, 761–763 (1979).
Ramos-Casals, M. et al. Sjögren syndrome or Sjögren disease? The histological and immunological bias caused by the 2002 criteria. Clin. Rev. Allergy Immunol. 38, 178–185 (2010).
Baer, A. N. & Hammitt, K. M. Sjögren’s disease, not syndrome. Arthritis Rheumatol. 73, 1347–1348 (2021).
Ramos-Casals, M. et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann. Rheum. Dis. 79, 3–18 (2020).
Mavragani, C. P. & Moutsopoulos, H. M. Primary versus secondary Sjögren syndrome: is it time to reconsider these terms? J. Rheumatol. 46, 665–666 (2019).
Kollert, F. & Fisher, B. A. Equal rights in autoimmunity: is Sjögren’s syndrome ever ‘secondary’? Rheumatology 59, 1218–1225 (2020).
Salliot, C. et al. Sjögren’s syndrome is associated with and not secondary to systemic sclerosis. Rheumatology 46, 321–326 (2007).
Felten, R., Meyer, A. & Gottenberg, J. Non-primary Sjögren’s Syndrome: secondary or associated? Jt. Bone Spine 90, 105502 (2023).
Panush, R. S., Wallace, D. J., Dorff, R. E. N. & Engleman, E. Retraction of the suggestion to use the term “Reiter’s syndrome” sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum. 56, 693–694 (2007).
Jennette, J. C. et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Falk, R. J. et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Ann. Rheum. Dis. 70, 704 (2011).
Beuers, U. et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis. Clin. Gastroenterol. Hepatol. 13, 1867–1869 (2015).
Nair, R., Aggarwal, R. & Khanna, D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin. Arthritis Rheum. 41, 95–105 (2011).
Vitali, C. et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European consensus group. Ann. Rheum. Dis. 61, 554–558 (2002).
Shiboski, C. H. et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 69, 35–45 (2017).
Vitali, C. et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum. 36, 340–347 (1993).
Brito-Zeron, P. et al. Exposure to air pollution as an environmental determinant of how Sjögren’s disease is expressed at diagnosis. Clin. Exp. Rheumatol. 41, 2448–2457 (2023).
Amezcua-Guerra L. M., et al. Joint involvement in primary Sjögren’s syndrome: an ultrasound “target area approach to arthritis”. Biomed. Res. Int. 2013, 640265 (2013).
Antero, D. C., Parra, A. G. M., Miyazaki, F. H., Gehlen, M. & Skare, T. L. Secondary Sjögren’s syndrome and disease activity of rheumatoid arthritis. Rev. Assoc. Med. Bras. 57, 319–322 (2011).
Assan, F., Mariette, X. & Nocturne, G. New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. Ann. Rheum. Dis. 80, e122 (2021).
Avouac, J. et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J. Rheumatol. 37, 608–614 (2010).
Avouac, J. et al. Systemic sclerosis-associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 54, 2243–2249 (2006).
Baer, A. N., Maynard, J. W., Shaikh, F., Magder, L. S. & Petri, M. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J. Rheumatol. 37, 1143–1149 (2010).
Baldini, C. et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin. Exp. Rheumatol. 31, 272–280 (2013).
Barcelos, F., Abreu, I., Patto, J. V., Trindade, H. & Teixeira, A. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren’s syndrome. Acta Reumatol. Port. 34, 608–612 (2009).
Bettero, R. G., Cebrian, R. F. M. & Skare, T. L. Prevalence of ocular manifestation in 198 patients with rheumatoid arthritis: a retrospective study. Arq. Bras. Oftalmol. 71, 365–369 (2008).
Brito-Zeron, P. et al. Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. Jt. Bone Spine 88, 105236 (2021).
Brown, L. E. et al. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology 54, 816–820 (2015).
Carmona, L. et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann. Rheum. Dis. 62, 897–900 (2003).
Colafrancesco, S. et al. Myositis in primary Sjögren’s syndrome: data from a multicentre cohort. Clin. Exp. Rheumatol. 33, 457–464 (2015).
Coustal, C. et al. Sjögren syndrome overlapping with ANCA-associated vasculitis: Four additional cases and systematic literature review. Autoimmun. Rev. 21, 103099 (2022).
Drosos, A. A., Voulgari, P. V., Psychos, D. N., Tsifetaki, N. & Bai, M. Sicca syndrome in patients with sarcoidosis. Rheumatol. Int. 18, 177–180 (1999).
Felten, R. et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology 60, 675–681 (2021).
Fragoulis, G. E. et al. Analysis of the cell populations composing the mononuclear cell infiltrates in the labial minor salivary glands from patients with rheumatoid arthritis and sicca syndrome. J. Autoimmun. 73, 85–91 (2016).
Gilboe, I. M., Kvien, T. K., Uhlig, T. & Husby, G. Sicca symptoms and secondary Sjögren’s syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann. Rheum. Dis. 60, 1103–1109 (2001).
Gottenberg, J. et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann. Rheum. Dis. 64, 114–117 (2005).
Guellec, D. et al. ANCA-associated vasculitis in patients with primary Sjögren’s syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun. Rev. 14, 742–750 (2015).
Haga, H., Naderi, Y., Moreno, A. M. & Peen, E. A study of the prevalence of sicca symptoms and secondary Sjögren’s syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int. J. Rheum. Dis. 15, 284–288 (2012).
Hajiabbasi, A., Shenavar Masooleh, I., Alizadeh, Y., Banikarimi, A. S. & Ghavidel Parsa, P. Secondary Sjögren’s syndrome in 83 patients with rheumatoid arthritis. Acta Med. Iran. 54, 448–453 (2016).
Hassold, N., Seror, R., Mariette, X. & Nocturne, G. Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis. RMD Open. 8, e002234 (2022).
Hernandez-Molina, G. et al. Similarities and differences between primary and secondary Sjögren’s syndrome. J. Rheumatol. 37, 800–808 (2010).
Hernandez-Molina, G. et al. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology 52, 1438–1442 (2013).
Iwamoto, N. et al. Determination of the subset of Sjögren’s syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. J. Rheumatol. 36, 113–115 (2009).
Iwamoto, N. et al. Magnetic resonance imaging of wrist and finger joints distinguishes secondary Sjögren’s syndrome with rheumatoid arthritis from primary Sjögren’s syndrome with articular manifestations. Clin. Exp. Rheumatol. 29, 1062–1063 (2011).
Jarrot, P. et al. Axial articular manifestations in primary Sjögren syndrome: association with spondyloarthritis. J. Rheumatol. 48, 1037–1046 (2021).
Kim, H. et al. The prevalence of Sjögren’s syndrome in rheumatoid arthritis patients and their clinical features. J. Korean Med. Sci. 35, e369 (2020).
Kobak, S., Kobak, A. C., Kabasakal, Y. & Doganavsargil, E. Sjögren’s syndrome in patients with ankylosing spondylitis. Clin. Rheumatol. 26, 173–175 (2007).
Kobak, S., Oksel, F., Aksu, K. & Kabasakal, Y. The frequency of sicca symptoms and Sjögren’s syndrome in patients with systemic sclerosis. Int. J. Rheum. Dis. 16, 88–92 (2013).
Kosrirukvongs, P., Ngowyutagon, P., Pusuwan, P., Koolvisoot, A. & Nilganuwong, S. Prevalence of dry eye syndrome and Sjögren’s syndrome in patients with rheumatoid arthritis. J. Med. Assoc. Thai 95 4, 61 (2012).
Levy, D. et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology 61, 756–763 (2022).
Manoussakis, M. N. et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 50, 882–891 (2004).
Mansour, M. J. et al. Sarcoidosis and Sjögren’s syndrome: clinical and salivary evaluation. J. Oral. Pathol. Med. 42, 594–599 (2013).
Mavragani, C. P., Fragoulis, G. E., Rontogianni, D., Kanariou, M. & Moutsopoulos, H. M. Elevated IgG4 serum levels among primary Sjögren’s syndrome patients: do they unmask underlying IgG4-related disease? Arthritis Care Res. 66, 773–777 (2014).
Melo, T. S., Silva, M. L. E., Silva Junior, M. Ld. M., Duarte, A. P. & Gueiros, L. A. Characterization of clinical, laboratory, IL-6 serum levels, and IL-6-174 G/C genetic polymorphisms in patients with rheumatoid arthritis and Sjögren’s syndrome. Rev. Assoc. Med. Bras. 67, 1600–1604 (2021).
Moerman, R. V. et al. 10-year follow-up of patients with rheumatoid arthritis and secondary Sjögren’s syndrome or sicca symptoms in daily clinical practice. Clin. Exp. Rheumatol. 38, 64–72 (2020).
Ng, A. L. K. et al. Comparison of tear osmolarity in rheumatoid arthritis patients with and without secondary Sjögren syndrome. Cornea 36, 805–809 (2017).
Oliveira, H. F. et al. Serologic profile and clinical markers of Sjögren syndrome in patients with rheumatoid arthritis. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 119, 628–635 (2015).
Pan, H. F. et al. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin. Rheumatol. 27, 339–343 (2008).
Payet, J. et al. ACPA-positive primary Sjögren’s syndrome: true primary or rheumatoid arthritis-associated Sjögren’s syndrome? RMD Open. 1, e000066 (2015).
Prabu, A. et al. Use of patient age and anti-Ro/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjögren’s syndrome. Rheumatology 42, 189–191 (2003).
Ramos-Casals, M., Brito-Zeron, P., Garcia-Carrasco, M. & Font, J. Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine 83, 85–95 (2004).
Ruacho, G. et al. Sjögren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state. J. Rheumatol. 47, 865–875 (2020).
Ryu, Y. et al. Follow-up of primary Sjögren’s syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol. Int. 33, 1443–1446 (2013).
Santosh, K. et al. Prevalence of secondary Sjögren’s syndrome in Indian patients with rheumatoid arthritis: a single-center study. Int. J. Rheum. Dis. 20, 870–874 (2017).
Scotto di Fazano, C. et al. Is the relationship between spondyloarthropathy and Sjögren’s syndrome in women coincidental? A study of 13 cases. Jt. Bone Spine 69, 383–387 (2002).
Sieiro Santos, C., Moriano Morales, C., Alvarez Castro, C. & Diez Alvarez, E. Polyautoimmunity in systemic lupus erythematosus: secondary Sjögren syndrome. Z. Rheumatol. 82, 68–73 (2023).
Szanto, A. et al. Clinical, serologic, and genetic profiles of patients with associated Sjögren’s syndrome and systemic lupus erythematosus. Hum. Immunol. 67, 924–930 (2006).
Wu, C. et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J. Dermatol. 44, 423–430 (2017).
Xu, D. et al. Sjögren’s syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case-control study. Lupus 19, 197–200 (2010).
Yang, H. et al. Clinical characteristics and risk factors for overlapping rheumatoid arthritis and Sjögren’s syndrome. Sci. Rep. 8, 6180–6181 (2018).
Yang, Y., Li, Z., Wang, L. & Zhang, F. The clinical and laboratory characteristics of Sjögren’s syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int. J. Rheum. Dis. 16, 173–177 (2013).
Ben Abdelghani, K. et al. Clinical and serological features of Sjögren syndrome in patients with rheumatoid arthritis. Br. J. Med. Med. Res. 5, 1287–1293 (2015).
Calvo, F., Karras, B. T., Phillips, R., Kimball, A. M. & Wolf, F. Diagnoses, syndromes, and diseases: a knowledge representation problem. AMIA Annu. Symp. Proc. 2003, 802 (2003).
Lenka, A. & Louis, E. D. Do we belittle essential tremor by calling it a syndrome rather than a disease? Yes. Front. Neurol. 11, 522687 (2020).
Brito-Zeron, P. et al. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study. EClinicalMedicine 61, 102062 (2023).
The Free Dictionary. What does SS stand for? (accessed 27 April 2025).
Ordonez-Canizares, M. C. et al. Frequency of polyautoimmunity in patients with rheumatoid arthritis and systemic lupus erythematosus. J. Clin. Rheumatol. 28, e38–e43 (2022).
Botello, A. et al. Prevalence of latent and overt polyautoimmunity in autoimmune thyroid disease: a systematic review and meta-analysis. Clin. Endocrinol. 93, 375–389 (2020).
Kalkan, C. & Soykan, I. Polyautoimmunity in autoimmune gastritis. Eur. J. Intern. Med. 31, 79–83 (2016).
Deretzi, G. et al. Polyautoimmunity in a Greek cohort of multiple sclerosis. Acta Neurol. Scand. 131, 225–230 (2015).
Amador-Patarroyo, M. J. et al. Sjögren’s syndrome at the crossroad of polyautoimmunity. J. Autoimmun. 39, 199–205 (2012).
Hudson, M. et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J. Autoimmun. 31, 156–159 (2008).
Lockshin, M. D., Levine, A. B. & Erkan, D. Patients with overlap autoimmune disease differ from those with ‘pure’ disease. Lupus Sci. Med. 2, e000084 (2015).
Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).
Martin-Gutierrez, L. et al. Stratification of patients with Sjögren’s syndrome and patients with systemic lupus erythematosus according to two shared immune cell signatures, with potential therapeutic implications. Arthritis Rheumatol. 73, 1626–1637 (2021).
Anaya, J. M., Rojas-Villarraga, A., Mantilla, R. D., Arcos-Burgos, M. & Sarmiento-Monroy, J. C. Polyautoimmunity in Sjögren syndrome. Rheum. Dis. Clin. North. Am. 42, 457–472 (2016).
Talal N. in Sjögren’s Syndrome: Clinical and Immunologic Aspects (eds Talal, N. et al.) vii–viii (Springer-Verlag, 1987).
Gottenberg, J. et al. Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjögren’s syndrome: post hoc analyses from the EMBODY trials. Arthritis Rheumatol. 70, 763–773 (2018).
Tsuboi, H. et al. Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid arthritis with Orencia trial toward Sjögren’s syndrome endocrinopathy) trial. Mod. Rheumatol. 26, 891–899 (2016).
